# Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

> **NCT02711007** · PHASE2,PHASE3 · COMPLETED · sponsor: **GUO WEI** · enrollment: 37 (actual)

## Conditions studied

- Osteosarcoma
- Metastasis

## Interventions

- **DRUG:** apatinib

## Key facts

- **NCT ID:** NCT02711007
- **Lead sponsor:** GUO WEI
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-12-30
- **Final completion:** 2018-01-08
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02711007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02711007, "Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02711007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*